For decades, the United States has devoted a significant portion of its healthcare spending to treating kidney disease. In fact, chronic kidney conditions and their complications account for nearly half of all medical costs in this country. This staggering figure tells us something important about where the real opportunities for improvement lie. If we want to improve healthcare outcomes and reduce expenses, we must solve this problem. That is the focus of Roivios. While many medical technologies branch outward into multiple applications, Roivios is doing the opposite: concentrating all of its efforts on restoring kidney function. Not because other conditions don’t matter, but because solving this particular problem would create one of the greatest impacts possible. 

To do that, the company is approaching kidney health in a fundamentally different way.

Why Roivios is focused exclusively on kidney function

When I look at healthcare in the United States, kidney disease is one of the biggest and most expensive problems we face. It accounts for a large part of overall medical spending, and the problems that come later only make that burden worse. That’s why Roivios is not trying to do everything at once. We are staying focused on restoring kidney function because solving this one problem would create more meaningful improvement, both in patient outcomes and in healthcare costs, than spreading our efforts across multiple smaller issues.

This discipline is intentional. I’ve always thought that the best way to make real progress is to focus on the problems that you can have the most impact on. This focus helps us work together, be efficient, and move quickly. The early clinical work we’ve done shows that this commitment is important. Recent studies and trial materials show that our approach could meaningfully improve kidney performance. This early approval makes me even more sure that staying focused is the right plan.

A different way of thinking about kidney restoration

To understand what we’re doing at Roivios, it helps to think about the kidney in simple terms. The kidneys are like a filter driven by pressure. There is high pressure at the top and low pressure at the bottom. When there is a healthy pressure difference, filtration works as it should. But in kidney disease, that gradient breaks down, and the system can no longer function effectively. It’s important to restore that natural balance if we want the kidney to recover.

For many years, the standard approach has been to push harder from the top of the system, increasing incoming pressure in hopes of forcing filtration to improve. But at Roivios, instead of increasing pressure at the top, we focus on safely lowering the pressure at the bottom to restore the natural balance that the kidney needs. When a problem continues even after years of trying, it’s usually not because you’re not trying hard enough. It’s more likely that you’re not going about it in the right way. Sometimes you need to completely change the way something works.

What early studies reveal about Roivios’ potential

The early studies and clinical materials we’ve produced show why this approach matters. By reducing pressure in the veins of the kidneys, we can see big improvements in how the kidneys work. This is especially helpful in cases where congestion is a major problem. When the pressure downstream is lower, the kidneys can adjust to the right level of pressure needed to work well. This allows them to filter the blood more naturally.

Some of the most compelling early signals involve patients with heart failure who also suffer from kidney complications. This group has historically had limited treatment options. The data suggests that addressing the pressure imbalance at the bottom of the kidney could offer clinicians a new way to treat kidney dysfunction related to congestion. While the research is still in the early stages, it supports the main idea behind Roivios. It suggests that a new approach to kidney restoration, where we focus on the smallest parts of the kidneys, may be more effective than the traditional strategies we’ve used for decades.

Featured studies:

• Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes (GRADIENT)
• Research Poster: Feasibility Study of a Novel Negative-Pressure Renal Assist Device (RAD) After Cardiac Surgery

You can find more of my reflections on this subject and others on my YouTube channel.